SynthesisJournal of neuro-oncology2021
Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.
Synthesis in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A Novel Nomogram for Predicting Meningioma Grade Based on Radiomics Features and Clinical Characteristics.Current medical science · 2026Article
- Extent of resection and adjuvant radiotherapy in intracranial anaplastic meningioma: improved disease control with no statistically significant overall survival benefit.Frontiers in surgery · 2026Article
- Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.Acta neurochirurgica · 2025Article
- Exploring the Role of Radiosurgery for Atypical Meningiomas: Addressing Suboptimal Local Control in High-Risk Patients.Advances in radiation oncology · 2025Article
- Neurocognitive evaluation in patients with intracranial Meningiomas: A systematic review.Brain & spine · 2025Review
- Prognostic role of extent of resection and adjuvant radiotherapy in de novo anaplastic meningiomas.Acta neurochirurgica · 2024Article
- Initial management of newly diagnosed WHO grade 2-3 adult meningioma following surgery: results from the Dutch Brain Tumour Registry (2016-2021).Journal of neuro-oncology · 2024Article
- The role of adjuvant radiotherapy for intracranial malignant meningiomas: analysis of a nationwide database.Journal of neuro-oncology · 2024Article
- Article
- Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery.Journal of neuro-oncology · 2024Article
- Meningioma recurrence: Time for an online prediction tool?Surgical neurology international · 2024Review
- Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center.Journal of neuro-oncology · 2023Article
- High grade spinal meningiomas: a rare but formidable challenge.Translational cancer research · 2023Article
- Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.Journal of neuro-oncology · 2023Article
- Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomasBiomedica : revista del Instituto Nacional de Salud · 2022Article
- Adjuvant radiotherapy in a case of atypical meningioma after gross total resection: an unresolved issue.BMJ case reports · 2021Article
- Article
- Lateral Ventricular Meningiomas: Clinical Features, Radiological Findings and Long-Term Outcomes.Cancer management and research · 2021Article
- Analysis of demographics and the impact of adjuvant radiotherapy on a nationwide cohort of patients with high-grade spinal meningiomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMeningiomas comprise 33% of all CNS tumors. The World Health Organization (WHO) describes meningiomas as benign (BM), atypical (AM), and malignant/anaplastic (MM). High-grade meningiomas such as AMs and MMs are more aggressive, recur more frequently, and portend a worse prognosis than BMs. Currently, the standard treatment for high-grade meningiomas, especially AMs, is ill-defined. In particular, the benefit to survival outcomes of adjuvant radiotherapy post-surgical resection remains unclear. In this study, we investigated the effect of adjuvant radiotherapy (ART) post-surgery on survival outcomes compared to surgery alone for high-grade meningiomas.
methodsPRISMA guidelines were a foundation for our literature review. We screened the PubMed database for studies reporting overall survival (OS), progression free survival (PFS), and tumor recurrence for intracranial, primary AM and MMs treated with surgery+ART or surgery alone. Fixed and random effect models compared tumor control rate for AM aforementioned groups.
resultsMean 5-year PFS was 76.9% for AM (surgery+ART) and 55.9% for AM (surgery alone) patients. Mean 5-year OS was 81.3% and 74% for AM (surgery+ART) and AM (surgery alone) groups, respectively. Overall, the mean 5-year PFS for aggregated high-grade meningiomas AM+MM (surgery+ART) was 67.6%. Fixed effect models revealed tumor control rate as 76% for AM (surgery+ART) and 69% for AM (surgery alone) groups. ART induced toxicity incidence ranged from 12.0% to 35.5% for AM and MM patients.
conclusionsOur analysis suggests that (surgery+ART) may increase PFS, OS, and tumor control rates in high-grade meningiomas. However, further studies involving surgery+ ART should be conducted to fully evaluate the ideal radiosurgical candidate, modality, and dosage.
Indexed as
Identifiers
33635510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.